Pfizer's combination drug, TALZENNA plus XTANDI, for prostate cancer has been granted Priority Review by the FDA for a label expansion. This development could significantly impact Pfizer's market position and investor sentiment.
Pfizer's Prostate Cancer Drug Receives FDA Priority Review
|1 min read
PFEPharmaceuticalsFDADrug ApprovalHealthcare
